AVXS-101/ZOLGENSMA is an approved gene therapy using an adeno-associated virus serotype 9 (AAV9) to deliver a functional copy of the SMN gene to MNs in patients with SMA. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.